In castrate metastatic PC, early-phase trials found that CAR-T cell therapy may target the prostate-specific membrane antigen (PSMA), a glycosylated type-II membrane protein that is upregulated in aggressive PCs [145,211]. The gene discussed is FOLH1; the disease is pachyonychia congenita.